4.6 Review

The biogenesis of active protein phosphatase 2A holoenzymes: a tightly regulated process creating phosphatase specificity

期刊

FEBS JOURNAL
卷 280, 期 2, 页码 644-661

出版社

WILEY
DOI: 10.1111/j.1742-4658.2012.08579.x

关键词

alpha 4; carboxymethylation; leucine carboxyl methyl transferase 1 (LCMT1); protein phosphatase type 2A methyl esterase 1 (PME-1); protein phosphatase type 2A (PP2A); protein phosphatase type 4 (PP4); protein phosphatase type 6 (PP6); peptidyl-prolyl cis; trans isomerase; phosphatase 2A phosphatase activator (PTPA); target of rapamycin signaling pathway regulator-like 1 (TIPRL1)

资金

  1. Research Foundation Flanders [G.0582.11N]
  2. Concerted Research Actions [GOA/2008/16, GOA/2012/12]
  3. Belgian Science Policy [IUAP P6/28]

向作者/读者索取更多资源

Protein phosphatase type 2A (PP2A) enzymes constitute a large family of Ser/Thr phosphatases with multiple functions in cellular signaling and physiology. The composition of heterotrimeric PP2A holoenzymes, resulting from the combinatorial assembly of a catalytic C subunit, a structural A subunit, and regulatory B-type subunit, provides the essential determinants for substrate specificity, subcellular targeting, and fine-tuning of phosphatase activity, largely explaining why PP2A is functionally involved in so many diverse physiological processes, sometimes in seemingly opposing ways. In this review, we highlight how PP2A holoenzyme biogenesis and enzymatic activity are controlled by a sophisticatedly coordinated network of five PP2A modulators, consisting of a4, phosphatase 2A phosphatase activator (PTPA), leucine carboxyl methyl transferase 1 (LCMT1), PP2A methyl esterase 1 (PME-1) and, potentially, target of rapamycin signaling pathway regulator-like 1 (TIPRL1), which serve to prevent promiscuous phosphatase activity until the holoenzyme is completely assembled. Likewise, these modulators may come into play when PP2A holoenzymes are disassembled following particular cellular stresses. Malfunctioning of these cellular control mechanisms contributes to human disease. The potential therapeutic benefits or pitfalls of interfering with these regulatory mechanisms will be briefly discussed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据